Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch
- Regulatory Remits
- Disentangling Pharmacotherapy from Psychotherapy
- Standardisation and Its Discontents
- Standardising Extra-Pharmacological Elements of Psychedelic Studies
- Standardising Adverse Event Definition and Reporting
- Blinding
- Indication Sequencing: TRD vs. MDD
- Safety & Post-Trial Support
- Relationship Between Subjective Effects and Therapeutic Outcomes
- Deficiencies in Present Data
- Predicting Treatment Response
- Rescheduling
- Incentivising Psychedelic Drug Development in the EU
On Tuesday the 16th and Wednesday the 17th of April, the European Medicines Agency (EMA) hosted a meeting in Amsterdam, “Multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework”.
Heavy rain and strong winds earlier in the week stunted Schiphol Airport’s capacity, making it a bad trip for some. Still, those attendees that made it to Amsterdam included academics, representatives from drug developers, lawyers, and so on.
Here, we don’t aim to provide a blow-by-blow account of the meeting, but instead share some thematic notes. I also focus more on the Q&A or interactive elements of the workshop, as those are generally where new information or angles are found...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks